The Food and Drug Administration (FDA) has issued a warning letter to Curalef Inc. of Wakefield, Massachusetts for illegally selling unapproved cannabidiol (CBD) products online with unsubstantiated health claims.
In patients with Parkinson disease who receive subthalamic nucleus deep brain stimulation, suicide behaviors tend to occur during the first 3 years after the procedure.
International Parkinson’s and Movement Disorder Society released recommendations on clinical screening instruments and rating scales used to measure impulsive and compulsive behaviors in Parkinson disease.
More frequent manic/mixed and depressive episodes were associated with an increased risk for Parkinson disease.
Parkinsonism is a lesser known debilitating adverse effect associated with valproate, especially in older patients.
There were no significant differences between pimavanserin and quetiapine in time to discontinuation, mortality, or improvement in psychosis in patients with Parkinson disease and Lewy body dementia.
Multiple genetic risk loci for Alzheimer disease predict longitudinal cognitive decline in patients with Parkinson disease without dementia.
Mindfulness yoga is a safe and effective treatment option for patients with mild-to-moderate Parkinson disease to help them manage stress and symptoms.
Motor complications are associated with suicidal ideation in Parkinson disease.
Kyowa Hakko Kirin announced that the FDA has accepted the resubmitted NDA for istradefylline for use as adjunctive treatment to levodopa/carbidopa in adults with Parkinson disease experiencing OFF episodes.
